Free press releases distribution network?

Agency / Source: Annodyne, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Annodyne Announces the Launch of its New Division - AIM Rx - Annodyne announces the launch of its new division: AIM Rx, a full-service digital health care agency with a concentrated focus on complex specialty markets - AimRx.com
Annodyne Announces the Launch of its New Division - AIM Rx

 

PRZOOM - /newswire/ - Blue Bell, PA, United States, 2014/03/07 - Annodyne announces the launch of its new division: AIM Rx, a full-service digital health care agency with a concentrated focus on complex specialty markets - AimRx.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Annodyne announces the launch of its new division: AIM Rx, a full-service digital health care agency with a concentrated focus on complex specialty markets (e.g., oncology, immunology, virology, neurology, metabolics and orphan designated conditions).

AIM Rx enters into the digital health care marketing scene with vast experience in the biopharma industry and agency experience across all target areas, including professional, payer and consumer. AIM Rx believes it’s this “one-of-a-kind blend of experience” that enables them to deliver fresh solutions that will help drive the future of health care marketing.

AIM Rx will be supported by a board of advisors, known as the Subject Matter Expert (SME) Panel, comprising experienced biopharma executives, marketers, sales professionals, payers and physicians from a variety of therapeutic areas, as well as leaders of nonprofit organizations. The SME Panel will serve to pressure-test the solutions AIM Rx develops for their clients so that they are better prepared to support the industry’s most pressing needs.

“With the U.S. health care landscape rapidly evolving, the biopharma sector needs new innovation from perspectives outside our industry,” said Dr. Michael Castagna, who is known as one of the industry’s change agents. “With Annodyne’s track record of success and AIM Rx’s focus on health care, I am confident they will provide unique viewpoints, capabilities and cutting-edge ideas the biopharma industry isn’t used to.”

AIM Rx has a proven history with traditional digital capabilities; however, their focus is on pre-launch engagement and awareness, payer solutions and customized social engagement platforms. Drawing on their varied experience and guided by the expert advisory panel, AIM Rx will leverage Ziel™, their proprietary audience engagement platform technology, to create fully connected environments of relevant stakeholders.

Ian Houck, director of client relations at AIM Rx said,“Our vision is to integrate and simplify the online patient and provider experiences within complex disease states to identify the right patient, connect them to the right community, and engage them with the right provider to ensure the highest level of care.”

The new agency is made up of four core departments: account services, creative, online marketing/media, and an in-house technology team. “In a landscape of all-too-similar agencies, AIM Rx is truly different,” added Houck. “We have the immediate resources to go head to head with large agencies, but we’re nimble enough to be able to customize our offerings to meet our clients’ specific needs.”

“We’re excited to launch this new division of Annodyne,” said Anthony Campisi, president and CEO of Annodyne, and managing director of AIM Rx. “And we’re anxious to leverage Annodyne’s capabilities to help evolve the digital landscape in the biopharma arena.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Annodyne, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Annodyne Announces the Launch of its New Division - AIM Rx

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Len Matty - Annodyne.com 
215-540-9110 lmatty[.]annodyne.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Annodyne, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Annodyne, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today